Hepatic fibrosis is usually resulted from prolonged liver injury caused by chronic hepatitis, alcohol or chemical insults. Cirrhosis, as the end stage of hepatic fibrosis, is a major clinical issue for its high prevalence in the world and its tight relationship with hepatocellular carcinoma incidence. Thus, great research efforts have been aimed at elucidating hepatic fibrogenesis and eventually finding a therapeutic way to abrogate its progression. 1, 2 Extensive studies have characterized hepatic fibrosis as an excessive and aberrant deposition of extracellular matrix (ECM) proteins in the liver, the most abundant of which is the collagen family. 3 Transforming growth factor-b (TGFb), a profibrotic cytokine with potent collagen synthesis stimulatory effect, plays a fundamental role through its intracellular signal transducers Smads in the pathogenesis of hepatic fibrosis. After TGFb-induced activation of the TGFb receptor, Smads are phosphorylated and translocated into the nucleus to transactivate expression of profibrotic target genes, ie, collagen type I. 4 Through decades of research, numerous molecules have been identified to be involved in the TGFb/Smad-mediated fibrogenesis. 5 Among them, a relatively new and thriving branch of work is focused on the role of co-activators in the fibrogenesis process. Ghosh and Varga implicate that co-activator p300/CBP contributes to fibroblast biology, connective tissue homeostasis and fibrosis. 6 TGFb responses are dramatically amplified with ectopic expression of p300/ CBP in fibroblasts, whereas selective p300 depletion results in abrogation of TGFb-induced Smads signaling and subsequent collagen synthesis. Another transcriptional co-activator P/CAF is reported to be able to potentiate transcriptional activity of heterologous Gal4-Smad2 and Gal4-Smad3 fusion proteins and TGF-b/Smad3-induced transcriptional responses in vitro, which can be further enhanced by co-activators p300 and Smad4. 7 In addition, Sylviane et al demonstrate that co-activator SRC-1, one of the p160 family members, works as a novel Smad3/4 transcriptional partner, facilitating the functional links between Smad3 and p300/CBP. 8 As one of the members of the p160 co-activator family, the steroid receptor co-activator-3 (SRC-3) is a broad-specificity transcriptional coregulator, which mediates the activating functions of nuclear receptors and other transcription factors. 9 Studies on the molecular mechanism of SRC-3 transactivation function reveal that SRC-3 interacts with other co-activators, ie, p300/CBP and P/CAF, 10 and forms a coactivator complex with them to facilitate gene transcription.
As new and emerging researches have emphasized an indispensable role of co-activators during Smads-mediated hepatic fibrogenesis and as SRC-3 is a co-activator essential for other cofactors such as p300/CBP and P/CAF to exert their functions, we investigate whether SRC-3 is involved in hepatic fibrosis through the TGFb/Smad pathway using a genetic SRC-3 ablation mice model. In this study, carbon tetrachloride (CCl 4 )-induced mice model was established to reveal the significance of SRC-3 in acute liver necrosis and chronic hepatic fibrosis. Our results show that SRC-3 À/À mice are protected against liver injury and fibrosis development as compared with SRC-3 þ / þ mice due to, at least in part, a defect in TGFb/Smad signaling.
MATERIALS AND METHODS Experimental Animals
The generation of SRC-3 À/À mice was described by Xu and Li. 9 Male, age matched (8-10 weeks old) SRC-3 À/À and wildtype mice (both in C57BL/6 Â 129Sv background) were used. Animals were maintained in humidity and temperature controlled rooms, kept on a 12 h light/dark cycle with free access to food and water. For acute liver damage study, the mice were killed 24, 36, 48 and 72 h, respectively, after a single intraperitoneal (i.p.) injection of 1 ml/kg body weight CCl 4 (1:7 v/v in olive oil). For chronic liver fibrosis study, the mice were administered i.p. with 0.5 ml/kg body weight CCl 4 (1:7 v/v in olive oil) twice per week for 3 and 6 weeks, separately. Mice were killed 3 days after the last CCl 4 administration. After killing, blood samples were obtained and livers were harvested for future analysis. No difference was observed in wild-type and SRC-3 À/À control mice injected i.p. with olive oil in both studies. All experiments were carried out under accepted ethical guidelines.
RNA Isolation and Quantitative PCR
Aliquots of liver tissue were snap-frozen and kept at À801C until RNA isolation. Total RNA was extracted from mouse livers using TRIzol reagent (Invitrogen, CA, USA). One microgram of sample RNA was transcribed to cDNA with the Reverse Transcription Kit (Promega Corp., WI, USA). Quantitative PCR was performed on the ABI 7900 Fast RealTime PCR System (Applied Biosystem, CA, USA) in 10 ml volume, using the SYBR Premix EX Taq Kit (Takara, Japan) under the manufacturer's instructions. The sequences of all used primers are available upon request. PCR array data were calculated by the DDC t method, normalized against housekeeping gene b-actin and expressed as mean fold change in SRC-3 À/À samples relative to SRC-3 þ / þ .
Histological Analysis and Collagen Content Measurement
Liver tissues were fixed in 4% formalin and embedded in paraffin according to the standard procedure. Paraffinembedded tissues were cut 5 mm thick and stained with hematoxylin and eosin (H&E) for morphological analysis or with Sirius Red (Sigma, MO, USA) for collagen content measurement. For computer quantification of collagen deposition, slides were prepared from the tissues of three individual mice of each genotype. Six fields were randomly selected per slide and calculated for collagen accumulation using Leica QWin software package under Â 10 objective. All slides were examined under the Nikon Eclipse80i microscope with Dxm1200F digital camera.
Terminal dUTP Nick-End Labeling Assay
Paraffin-embedded liver tissues were assayed for DNA fragmentation using a terminal deoxynucleotidyl transferasemediated dUTP-biotin nick-end labeling (TUNEL) reaction according to the manufacturer's instructions (Roche, IN, USA). Results were examined under a fluorescence Nikon Eclipse80i microscope. To quantitate the TUNEL-positive cells, slides were prepared from the tissues of three individual mice of each genotype and assayed for TUNEL reaction as described above. Ten fields were then randomly selected per slide at Â 400 magnification. TUNEL-positive cells were counted on each field and averaged to give the TUNELpositive cells per field.
Western Blotting
Lysates from liver tissues were separated on SDS-PAGE, transferred to nitrocellulose and blotted with primary antibodies directed against Collagen Type I (Boster, Wuhan, China), anti-smooth muscle a-actin (a-SMA, Sigma), TGFb1 (Sigma), Smad2, phospho-Smad2, Smad3, phospho-Smad3, Cyclin D1, Bcl2-associated X-protein (Bax, all purchased from Cell Signaling, MA, USA) and glyceraldehtde-3-phosphate dehydrogenase (GAPDH, Cell signaling, as loading control) followed by appropriate secondary antibodies and chemiluminescent detection. 
Immunohistochemistry
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To assess the extent of fibrosis in samples of viral hepatitis or hepatic cirrhosis, the slide containing the microarray was dewaxed and rehydrated with the standard procedure and stained with Sirius Red to show the fibrotic area. The fibrotic area was then graded into four groups based on the overall intensity and the percentage of stained area of each sample (À, negative; þ , low; þ þ , moderate; and þ þ þ , strong) at Â 100 magnification by experienced, unbiased histology technicians. Variations in grading between the two observers were identified and the cases were individually discussed and a final consensus was made. The Kruskal-Wallis test was used to evaluate the difference in the extent of fibrosis (all four groups) between the human samples of viral hepatitis and hepatic cirrhosis.
For SRC-3 immunoreactivity, the slide containing the microarray was processed according to the standard immunohistological procedure with a primary antibody against human SRC-3. The positive SRC-3 nucleus staining rate of each sample was evaluated quantitatively by experienced, unbiased histology technicians and divided into four groups (À, negative; þ , o30% positive rate; þ þ , 30-60% positive rate; and þ þ þ , 460% positive rate). The Kruskal-Wallis test was used to evaluate the difference in the intensity of SRC-3 nucleus staining (all four groups) between the human samples of viral hepatitis and hepatic cirrhosis. Correlation between SRC-3 staining intensity and the grades of Sirius Red staining was evaluated by Spearman's rank correlation.
ELISA Assay and Biochemistry Analysis
Enzyme-linked immunosorbent assay (ELISA) was performed with the mouse TGFb1 immunoassay kit (R&D systems, MN, USA) following the manufacturer's instructions. Each sample was assayed in duplicate. Serum alanine transaminase (ALT) activity was measured by the Department of Clinical Chemistry, Ruijin Hospital, using automated procedures.
Statistics
Animal experiments were performed with between 6 and 10 animals per experimental group. Results were expressed as the mean ± s.d. Comparisons between groups were performed using t-test (GraphPad Prism version 4.03), the Kruskal-Wallis test (SAS 8.0 statistical software) or the Spearman's rank correlation (SPSS 13.0 statistical software). Differences were considered significant if Po0.05. mice. ALT level had a mild but not significant decrease in SRC-3 À/À mice compared with SRC-3 þ / þ mice 36 h after CCl 4 challenge. When ALT levels started to decrease in mice from both genotypes 48 h after the insult, the difference became apparent as ALT level was significantly lower in SRC-3 À/À mice than SRC-3 þ / þ mice at this time point. Then, at 72 h, ALT levels dropped back to the levels seen before CCl 4 treatment in both SRC-3 þ / þ and SRC-3 À/À mice. Acute CCl 4 -induced liver injury can also be reflected by the upregulation of proteins involved in the profibrotic response. 12 As shown in Figure 1c , CCl 4 insult-induced elevation of TGFb1, collagen Type I and a-SMA expression were significantly suppressed in SRC-3 À/À mice 48 h after liver intoxication, which was in consistent with our histological and serological findings. These results indicate that SRC-3 À/À mice were protected against acute CCl 4 -induced liver damage, possibly due to an early-onset of tissue recovery.
RESULTS
Enhanced Hepatocyte Proliferation and Suppressed Hepatocyte Apoptosis in SRC-3
À/À Mice after Acute CCl 4 Injection As acute liver necrosis and profibrotic response were significantly ameliorated in SRC-3 À/À mice 48 h after CCl 4 injection (Figures 1c and 2a) , we focused on the CCl 4 -treated mice from this time point to study the intrinsic mechanism. The increase in TGFb1 serum level was significantly blunted in SRC-3 À/À mice compared with wild-type mice (Figure 2b ), which was in consistent with its tissue expression level presented in Figure 1c . As the hallmark of liver injury and a major profibrogenic cytokine, TGFb1 has been reported to be a potent proliferation inhibitor and apoptosis inducer in hepatocytes. 13, 14 Thus, hepatocyte proliferation and apopto-SRC-3 À/À attenuates liver injury and fibrosis X Ma et al sis were examined in SRC-3 þ / þ and SRC-3 À/À mice 48 h after CCl 4 administration. As shown in Figure 2c and d, hepatocyte proliferation was significantly elevated in SRC-3 À/À mice compared with SRC-3 þ / þ as shown by PCNA immunochemistry staining on liver sections. Besides necrosis, hepatocytes may undergo apoptosis in response to CCl 4 treatment. TUNEL assay revealed a significant reduction in the number of apoptotic hepatocytes in SRC-3 À/À mice compared with SRC-3 þ / þ mice (Figure 2e and f). These data suggested that hepatocyte proliferation was enhanced while apoptosis was reduced in SRC-3 À/À mice after acute CCl 4 injection, probably due to suppressed TGFb1 induction in the lack of SRC-3.
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À/À Mice are Protected Against Chronic Hepatic Fibrosis The enhanced tissue damage repair and the decreased profibrotic response discovered in SRC-3 À/À mice after acute CCl 4 administration suggested that the knockout mice might also be protected against chronic hepatic fibrosis. To address this question, we subjected SRC-3 þ / þ and SRC-3 À/À mice under prolonged CCl 4 treatment. After 3 and 6 weeks of CCl 4 administration, SRC-3 þ / þ mice had prominently more inflammatory infiltration in the liver compared with similarly treated SRC-3
À/À mice as demonstrated by histological analysis (Figure 3a ) and CD8 immunofluorence analysis (Figure 3b ). Similar to mice treated acutely with CCl 4 , serum TGFb1 level was lower in SRC-3 À/À mice versus SRC-3 þ / þ mice ( Figure 3c ). Next, we examined a-SMA expression in the livers from SRC-3 þ / þ and SRC-3 À/À mice as it is a wellaccepted marker for hepatic stellate cell (HSC) activation. Stronger intensity of a-SMA immunohistological staining and significantly more a-SMA-positive cells were observed in liver sections of SRC-3 þ / þ mice than that of SRC-3 À/À mice (Figure 3d ). Consistently, a-SMA mRNA expression level was elevated in the livers of SRC-3 þ / þ mice compared with administration. GAPDH was used as an invariant control. All data are mean ± s.e. **Po0.01, WT vs KO. (Figure 3e ). Sirius Red staining for collagen deposition showed that SRC-3 þ / þ mice developed extensive fibrosis, disclosing a honeycomb pattern of fibrous septa, bridging the centrilobular veins, whereas collagen accumulation was greatly subdued in SRC-3 À/À mice (Figure 3f ). Digital quantification of fibrotic area confirmed this observation (Figure 3 g ). All these data indicated that under prolonged CCl 4 treatment, SRC-3 À/À mice were resistant to chronic hepatic fibrosis as demonstrated by the significant reduction in inflammatory infiltration, TGFb1 secretion, HSC activation and collagen accumulation.
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Altered Fibrotic Gene Expression, Reduced Hepatocyte Apoptosis and Increased Hepatocyte Proliferation in SRC-3 À/À Mice As hepatic fibrosis was attenuated in SRC-3 À/À mice after both 3 and 6 weeks CCl 4 treatment, with a more significant difference between SRC-3 þ / þ and SRC-3 À/À mice in the 3-week-treatment group, we used the CCl 4 -treated mice from this experiment group for further investigation. The mRNA expression levels of the collagen family molecules were significantly reduced in SRC-3 À/À mice compared with wildtype mice (Figure 4a ), which was in accordance with the results from Sirius Red staining analysis (Figure 3f and g ). Moreover, expression levels of matrix metalloproteinases (MMPs), a proteolytic enzyme family involved in HSC activation and hepatic fibrosis process, 15 were much lower in SRC-3 À/À mice than SRC-3 þ / þ mice (Figure 4b ). Similar to mice after acute CCl 4 treatment, in SRC-3 À/À mice with chronic CCl 4 administration, hepatocyte proliferation was enhanced as demonstrated by PCNA immunostaining (Figure 4c and d) and hepatocyte apoptosis was suppressed as revealed by TUNEL assay (Figure 4e and f) . Furthermore, similar results on PCNA staining and TUNEL assay were obtained using 6-week-treated mice (Supplementary Figure 1) . Collectively, these data confirmed our previous observation that chronic fibrosis was attenuated in SRC-3 À/À mice.
SRC-3 Ablation Impairs TGFb1/Smad Signaling
The results we obtained from the SRC-3 À/À chronic fibrosis mice models were similar with our observations in the SRC-3 À/À acute necrosis mice models, with significantly reduced TGFb1 serum levels in both models. This motivated us to examine whether the altered TGFb1/Smad signaling, the key profibrogenesis pathway, in SRC-3 À/À mice could be the inner mechanism behind its resistance to CCl 4 -induced fibrosis. As shown in Figure 5a , the TGFb1 protein expression level was sharply decreased in the liver of SRC-3 À/À mice compared with SRC-3 þ / þ mice. Meanwhile, the expressions of phospho-Smad2 and phospho-Smad3, mediators of the TGFb1 signaling, were also greatly suppressed in SRC-3 À/À mice. No significant difference in Smad2 and Smad3 total protein levels was observed between the two genotypes. Consistently, the liver lysates from SRC-3 À/À mice showed increased cell cycle-promoting molecule CyclinD1 and decreased proapoptotic molecule Bax expression levels, both were reported to be the targets of TGFb1/Smad pathway ( Figure 5b ). Similar results were obtained on 6-week-treated mice (Supplementary Figure 2) . These data indicated that SRC-3 À/À mice were protected against chronic hepatic fibrosis, at least partially, due to impaired TGFb1/Smad signaling.
Positive Correlation between SRC-3 and Degrees of Fibrosis in Human Hepatic Diseases
Various degrees of hepatic fibrosis are frequently observed in the livers of patients with chronic hepatitis, and prolonged hepatic fibrosis will finally result in hepatic cirrhosis. 16 To study the expression of SRC-3 gene in fibrogenesis progression, we further analyzed SRC-3 immunoreactivity in a human tissue microarray consisting of human hepatic disease samples, including viral hepatitis, hepatic cirrhosis and hepatocellular carcinomas (HCC). As demonstrated by the Kruskal-Wallis test, the degrees of fibrosis in the samples of hepatic cirrhosis were significantly stronger than that in the samples of viral hepatitis (Figure 6a-d and Supplementary Table 1 ). Positive SRC-3 immunoreactivity showed a diffuse intra-cytoplasmic granular staining and part of nucleus staining in liver sections prepared from patients. As SRC-3 exerts its function in the nucleus, positive rates of SRC-3 nucleus staining were graded (see MATERIALS AND METHODS) and studied. As shown in Table 1 , 68% of the hepatitis group stained negative (À) for SRC-3 im- SRC-3 À/À attenuates liver injury and fibrosis X Ma et al munoreactivity and no samples from this group showed strong SRC-3 staining ( þ þ þ ). In contrast, only 23% of the cirrhosis group had negative staining and it had higher percentages of samples with various SRC-3 staining amplitude ( þ , þ þ and þ þ þ ) than the hepatitis group. The Kruskal-Wallis test demonstrated that the intensity of SRC-3 immunoreactive staining showed a statistically different pattern between the hepatitis and the cirrhosis samples (Figure 6e-h and Table 1 ). Furthermore, Spearman's correlation test showed that the intensity of SRC-3 nucleus immunoreactivity and the degrees of fibrosis in each sample were significantly correlated (r ¼ 0.462, P ¼ 0.008).
Compared with other groups, HCC group had the highest percentage of samples with strong SRC-3 staining ( þ þ þ ) (Supplementary Figure 3) and served as a positive control, as SRC-3 has been identified as an oncogene in the liver and was reported to be overamplified in hepatocellular carcinoma. 17 These data from clinical human samples suggested that SRC-3 expression level was positively correlated with hepatic fibrosis extent in human hepatic diseases.
DISCUSSION
This study shows that SRC-3 plays an important role in liver injury and fibrogenesis. Mice lacking SRC-3 have attenuated mice had similar liver damage 24 and 36 h after the insult, but the necrosis extent was greatly ameliorated after 48 h in SRC-3 À/À mice, whereas severe hepatic damage in SRC-3
mice remained, as demonstrated by histological analysis and serum ALT levels from both genotypes. This inspired us to examine hepatocyte proliferation 12 in SRC-3 þ / þ and SRC-3 À/À mice. The expression level of PCNA, a nuclear protein highly expressed during the DNA synthesis phase of the cell cycle, is tightly correlated with the proliferative state of the cells. 18 PCNA expression was significantly elevated in SRC-3 À/À mice, indicating an increase in hepatocyte proliferation in the lack of SRC-3, which could lead to the enhanced hepatic damage repair and thus the significantly alleviated necrosis in SRC-3 À/À mice observed 48 h after CCl 4 challenge. It should be noted that upon CCl 4 treatment, SRC-3 þ / þ mice demonstrated significant necrotic lesion and dramatically increased serum ALT level. Interestingly, in a previous report, injection of another hepatotoxin, lipopolysaccharide, causes only a mild hepatic injury with a small increase in serum ALT levels in both SRC-3 À/À and SRC-3 þ / þ mice. 19 It seems that lipopolysaccharide, as a hepatotoxin, is not involved in the promotion of acute liver damage, which is different from CCl 4 .
In response to CCl 4 treatment, hepatocytes may undergo apoptosis in addition to necrosis. 12 In our mice models under both acute and chronic CCl 4 administration, suppressed hepatocyte apoptosis and reduced proapoptotic protein Bax expression were observed in the livers of SRC-3 À/À mice. Apoptosis of hepatocytes is one of the major promoting factors in the development of liver fibrosis. Mehal' group demonstrates that DNA from apoptotic hepatocytes acts as an important mediator of HSC differentiation by stopping mobile HSCs around the apoptosing hepatocytes and inducing HSC collagen production, thus promotes liver fibrogenesis. 20 We observed suppressed HSC activation, significantly suppressed Collagen I messenger RNA levels and less collagen accumulation in SRC-3 À/À mice, which might be contributed in part by the reduced hepatocyte apoptosis in the absence of SRC-3.
In liver tissue, the MMP family plays a pivotal role in hepatic fibrosis. The current knowledge obtained from various literatures showed that MMPs might play different roles in fibrogenesis and fibrolysis. 15 Literature that focused on the fibrogenesis process indicated a fibrosis-promoting role of the MMPs family. For example, MMP-2 mRNA expression increases during experimental fibrogenesis induced by CCl 4 injections and remains elevated, while its activation is mediated by MMP-14.
21-24 MMP-2 and MMP-14 are expressed by HSCs during their activation following liver injury, which are important for HSC proliferation and migration. [25] [26] [27] MMP-9 is produced by various cell types in CCl 4 -induced liver injury, the activity of which is not associated with the degree of fibrosis but usually links to the histologically derived level of tissue inflammation. 21 MMP-9 can activate latent TGF-b, 28 which is vital in earlier stages of fibrogenesis, as collagen production of HSCs is stimulated by TGF-b. 29 The important role of MMP-9 in the initial phase of HSC activation is identified by French's group, as IL-1a-induced HSC activation is completely prevented by deprivation of MMP-9.
30 MMP13 has the ability to destroy normal liver tissue for newly synthesized ECM deposition and ECM-bound cytokines, ie, TGFb1 releasing, subsequently induces fibrogenesis. 31, 32 At the same time, studies emphasized on the fibrolysis process using fibrosis regression mice models indicated that an elevation in MMPs expression could enhance the liver recovery from fibrosis. For instance, during regression from liver fibrosis, MMP-13 and MMP-14 have the ability to degrade abnormal fibrillar collagen, thus might be responsible for key events in ECM degradation. 33, 34 Other studies implied that MMP-2 and MMP-9 might contribute indirectly to fibrolysis for their association with HSCs apoptosis. 35, 36 In our study, the mice were killed 3 days after the last CCl 4 injection and thus might have been in the fibrogenesis-developing stage not in the fibrosis regression stage. It is therefore possible that the significant decrease in the MMPs mRNA expression levels in SRC-3 À/À mice compared with the similarly treated wild-type mice could contribute to the resistance to chronic hepatic fibrosis in SRC-3 À/À mice. Moreover, HSC activation, inflammatory infiltration, collagen accumulation as well as TGFb1 secretion were all suppressed in SRC-3 À/À mice compared with SRC-3 þ / þ mice, which were in consistent with the reduction levels of MMPs and their roles in fibrogenesis. SRC-3 is reported to directly regulate the transcription of MMP-2 and MMP-13 through its coactivation of AP-1 and PEA3, 37 which Immunohistochemistry study of the SRC-3 gene in human viral hepatitis and hepatic cirrhosis indicated that SRC-3 expression correlated positively with fibrosis extent. a Compared with viral hepatitis group, P ¼ 0.012.
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À/À attenuates liver injury and fibrosis X Ma et al suggested that alterations in the MMPs expression levels caused by SRC-3 ablation could be one of the possible reasons for the fibrosis resistance in SRC-3 À/À mice. During the development of hepatic fibrosis, aberrant activity of TGF-b1 and its downstream signal transducers Smads have been proved to be vital to the progression of fibrogenesis at both cellular and molecular levels. 38 Upon TGF-b1 binding to its receptor, the receptor associated Smads (Smads 1, 2, 3, 5 and 8) are phosphorylated, form a complex with the co-Smad (Smad4), and translocate into the nucleus to regulate transcription of profibrotic target genes. 38 TGF-b1/Smad signaling pathway can influence various aspects in the fibrogenesis process, including inhibition of hepatocyte proliferation, 39 induction of hepatocyte apoptosis, 40, 41 and of utmost importance, mediation of HSC acitivation 42 and the subsequent stimulation of HSC collagen secretion. 29 In our CCl 4 -treated mice models, the TGF-b1 serum level was significantly decreased in SRC-3 À/À mice compared with SRC-3 þ / þ mice. Further detailed examinations revealed that protein expression levels of liver TGF-b1, phospho-Smad2 and phospho-Smad3 were sharply reduced in the absence of SRC-3. Changes in the collagen family, Cyclin D1 and Bax expression levels, which have been reported to be responsive to TGF-b1/Smad regulation, [43] [44] [45] confirmed our discovery. These results indicated that TGFb1/Smad signaling was impaired in SRC-3 À/À mice, which in turn causing enhanced hepatic damage repair, reduced hepatocyte apoptosis, suppressed HSC activation and decreased collagen production, thus protected SRC-3 À/À mice against CCl 4 -induced acute liver necrosis and, more importantly, chronic hepatic fibrosis.
Steroid receptor co-activator-3 plays a critical role in gene transcription through its interaction with co-activator p300/ CBP and P/CAF, 10 and it is clear that co-activator p300/CBP 6 and P/CAF 7 are essential for Smads-mediated transcriptional activity. As a family member to SRC-3, SRC-1 is demonstrated to be able to enhance TGFb-induced, Smad-mediated transcription in vitro through its interaction with p300/CBP. 8 Therefore, SRC-3 can exert its influence on TGF-b1/Smad signaling through its interaction with p300/CBP and/or P/CAF or by forming a functional co-activator complex with them, and regulate hepatic fibrogenesis independently or synergistically with its family members during different pathologic phases. The detailed molecular mechanism of the regulation of SRC-3 on TGF-b1/Smad signaling will be the focus of our future work. It will also be useful to create an SRC-1/SRC-3 double knockout mouse strain to study the specificity and redundancy of the p160 family members during hepatic fibrogenesis.
Finally, we evaluated the SRC-3 expression levels in the liver specimens from patients with hepatic fibrosis, cirrhosis or HCC by immunohistochemistry analysis. For fibrosis and cirrhosis samples, the intensity of SRC-3 immunostaining in nucleus was positively linked to the severity of hepatic fibrosis extent, with strong intensity in cirrhosis specimens and moderate in fibrosis ones. These results were in consistent with the data obtained from our SRC-3-deficient mice models, which suggested that SRC-3 also played a crucial role in the pathogenesis of human fibrosis and cirrhosis. Besides, we also investigated the expression of SRC-3 in HCC samples. The finding showed that SRC-3 was overamplified in hepatocellular carcinoma, which was confirmed by previous data, indicating that SRC-3 was a tumor-promoting oncogene in the liver. 17 In summary, our study demonstrates that SRC-3 plays a vital role in the progression of fibrosis using an in vivo mice model. In SRC-3 À/À mice, acute liver injury and chronic hepatic fibrosis induced by CCl 4 administration are less severe as compared with their wild-type littermates. The protective effect of SRC-3 ablation is mediated, at least partially, through the impaired TGF-b1/Smad signaling in SRC-3 À/À mice. Moreover, clinical samples show that SRC-3 expression levels are tightly correlated with extents of hepatic fibrosis. These findings establish an essential involvement of SRC-3 in liver fibrogenesis, which may provide new clues to the future treatment of hepatic fibrosis.
